Obstructive sleep apnea severity, circulating biomarkers, and cancer risk
CONCLUSIONS: OSA severity was an independent risk factor for cancer. Furthermore, two circulating markers were significantly associated with cancer risk. If these preliminary findings can be reproduced in other cohorts, biomarkers could potentially be used to prognosticate OSA patients with respect to cancer risk.PMID:38648119 | DOI:10.5664/jcsm.11170 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: A J Hirsch Allen Tetyana Kendzerska Parveen Bhatti Rachel Jen Renelle Myers Mohammadreza Hajipour Stephan F van Eeden Najib Ayas Source Type: research
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
CONCLUSION: Liposomal irinotecan and topotecan demonstrated similar median OS and PFS in patients with relapsed SCLC. Although the primary end point of OS was not met, liposomal irinotecan demonstrated a higher ORR than topotecan. The safety profile of liposomal irinotecan was consistent with its known safety profile; no new safety concerns emerged.PMID:38648575 | DOI:10.1200/JCO.23.02110 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: David R Spigel Afshin Dowlati Yuanbin Chen Alejandro Navarro James Chih-Hsin Yang Goran Stojanovic Maria Jove Patricia Rich Zoran G Andric Yi-Long Wu Charles M Rudin Huanyu Chen Li Zhang Stanley Yeung Fawzi Benzaghou Luis Paz-Ares Paul A Bunn RESILIENT Tr Source Type: research
Dosimetric Impact of Delineation and Motion Uncertainties on the Heart and Substructures in Lung Cancer Radiotherapy
CONCLUSION: Radiotherapy dose uncertainties from delineation variations and respiratory-related heart motion were quantified using a cardiac substructure automatic segmentation tool. This predicts the 'dose range' where doses to structures are most likely to fall, rather than single DVH curves. This enables consideration of these uncertainties in cardiotoxicity research and for future plan optimisation. The tool was designed for cardiac structures, but similar methods are potentially applicable to other OARs.PMID:38649309 | DOI:10.1016/j.clon.2024.04.002 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: V Chin R N Finnegan P Chlap L Holloway D I Thwaites J Otton G P Delaney S K Vinod Source Type: research
Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
CONCLUSIONS: The incidence and risk factors of HPD varied with different definitions, but mHPD identified more cases with poor outcomes. This comprehensive approach may enhance the identification of at-risk patients and lead to a better understanding of HPD in lung cancer during immunotherapy.PMID:38644088 | DOI:10.1016/j.cllc.2024.03.001 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Trie Arni Djunadi Youjin Oh Jeeyeon Lee Jisang Yu Liam Il-Young Chung Yeunho Lee Leeseul Kim Timothy Hong Soowon Lee Zunairah Shah Joo Hee Park Sung Mi Yoon Young Kwang Chae Source Type: research
Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice
Clin Exp Med. 2024 Apr 20;24(1):80. doi: 10.1007/s10238-024-01342-y.ABSTRACTPeritoneal mesothelioma (PeM) is an aggressive tumor with limited treatment options. The current study aimed to evaluate the value of next generation sequencing (NGS) of PeM samples in current practice. Foundation Medicine F1CDx NGS was performed on 20 tumor samples. This platform assesses 360 commonly somatically mutated genes in solid tumors and provides a genomic signature. Based on the detected mutations, potentially effective targeted therapies were identified. NGS was successful in 19 cases. Tumor mutational burden (TMB) was low in 10 cases, ...
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Job P van Kooten Michelle V Dietz Hendrikus Jan Dubbink Cornelis Verhoef Joachim G J V Aerts Eva V E Madsen Jan H von der Th üsen Source Type: research
Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China
CONCLUSION: Patients with lung cancer require more ICU care due to critical complications and the overall survival prognosis is poor. Colorectal cancer may benefit more from ICU management. This information may be considered in ICU admission and treatment strategies.PMID:38642154 | PMC:PMC11032264 | DOI:10.1007/s00432-024-05727-0 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Wensheng Liu Dongmin Zhou Li Zhang Mingguang Huang Rongxi Quan Rui Xia Yong Ye Guoxing Zhang Zhuping Shen Cancer Critical Care Medicine Committee of the Chinese Anti-Cancer Association Source Type: research
Automated treatment planning for whole breast irradiation with individualized tangential IMRT fields
CONCLUSIONS: Although our attempt to correlate patient anatomical features with planning strategy using machine learning tools was unsuccessful, the resulting dosimetric outcomes proved satisfactory. Our algorithm consistently produced high-quality plans, offering significant time and efficiency advantages.PMID:38642406 | DOI:10.1002/acm2.14361 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Giulianne Rivelli Rodrigues Zaratim Ricardo Gomes Dos Reis Marcos Ant ônio Dos Santos Nathalya Ala Yagi Luis Felipe Oliveira E Silva Source Type: research
Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics
J Clin Pharmacol. 2024 Apr 19. doi: 10.1002/jcph.2435. Online ahead of print.ABSTRACTTrilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of tr...
Source: Clinical Lung Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Chao Li Richard A Preston Emily Dumas Andrew Beelen Thomas C Marbury Source Type: research
The Effect of Vaccination with Pfizer-BioNTech or CoronaVac on Disease Prognosis Among Hospitalized COVID-19 Patients
CONCLUSION: Among the inpatients with COVID-19, the predictors for mortality were being unvaccinated, older age, cancer, chronic kidney disease, and cardiovascular diseases. Among the vaccinated inpatients, having two doses of the Pfizer-BioNTech vaccine was the only effective protective measure against mortality, and two doses of the CoronaVac vaccine had no significant effect in preventing fatality.PMID:38633010 | PMC:PMC10985826 | DOI:10.36519/idcm.2023.226 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Mustafa G üldan Sena Tu ğana Ateş Sebile Sar ıoğlu Sarp Suyabatmaz Pelin İrkören S üda Tekin Mahir Kapmaz Şiran Keske Önder Ergönül Source Type: research
Age, Gender, and Liver Enzyme Impact Hospital Stay in COVID-19 Minority Patient with Cancer in the USA: Does Race Matters in the Pandemic?
Ann Clin Med Case Rep. 2024;13:7. Epub 2024 Mar 21.ABSTRACTPatients with cancer are known to have a poor prognosis when infected with SARS-CoV-2 infection. We aimed in this study to assess health outcomes in COVID-19 patients with different cancers in comparison to non-cancer COVID-19 patients from different centers in the United States (US). We evaluated medical records of 1,943 COVID-19 Cancer patients from 3 hospitals admitted between December 2019 to October 2021 and compared them with non-cancer COVID-19 patients. Among 1,943 hospitalized COVID-19 patients, 18.7% (n=364) have an active or previous history of cancer. A...
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: H Ashktorab G Oskrochi S R Challa L G Chirumamilla S Saroya S Dusmatova N Shayegh V Nair K Senthilvelan D Byer N Morrison B Grossi A Barclay T Smith K Watson M Rashid R Rashid M Deverapalli G Latella J M Carethers A Youssef H Brim Source Type: research
The impact of advancing the standard of care in radiotherapy on operational treatment resources
CONCLUSION: The clinical implementation of hypofractionated treatment regimens has successfully reduced the radiotherapy workload and operational treatment hours required to treat patients. This analysis describes the impact of changes to the standard of care on institutional resources.PMID:38634814 | DOI:10.1002/acm2.14363 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Michael Roumeliotis Kundan Thind Hali Morrison Ben Burke Kevin Martell Lukas van Dyke Lisa Barbera Sarah Quirk Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis
CONCLUSION: The C + R nomograms were more effective in predicting EGFR-TKI efficacy of EGFR-mutant NSCLC patients with brain metastases than single clinical or radiomics nomograms.PMID:38637187 | DOI:10.1016/j.crad.2024.02.016 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: H Qi Y Hou Z Zheng M Zheng X Sun L Xing Source Type: research
Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer
CONCLUSIONS: In ALK+ NSCLC, longer EML4-ALK variants correlate with improved prognosis and enhanced response to second-generation ALKi, while TP53 co-mutations indicate a negative prognosis.PMID:38637357 | DOI:10.1007/s12094-024-03481-w (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Ying Fu Qing Liu Xiaohan Wang Liangchao Sun Xiao Han Xue Meng Source Type: research
Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer
CONCLUSIONS: CLDN4 could be considered as a predictive marker of recurrent MPE among patients with advanced NSCLC. Further validation for its clinical value in cohorts with larger sample size and in-depth mechanism studies on its biological function are warranted.TRIAL REGISTRATION: Not applicable.PMID:38629624 | PMC:PMC11022306 | DOI:10.1002/ctm2.1649 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Xiaoshen Zhang Xuanhe Wang Yaokai Wen Shen Chen Caicun Zhou Fengying Wu Source Type: research
